DK1679319T3 - Fremgangsmåde til forebyggelse og behandling af Alzheimers sygdom (AD) - Google Patents

Fremgangsmåde til forebyggelse og behandling af Alzheimers sygdom (AD)

Info

Publication number
DK1679319T3
DK1679319T3 DK05107898T DK05107898T DK1679319T3 DK 1679319 T3 DK1679319 T3 DK 1679319T3 DK 05107898 T DK05107898 T DK 05107898T DK 05107898 T DK05107898 T DK 05107898T DK 1679319 T3 DK1679319 T3 DK 1679319T3
Authority
DK
Denmark
Prior art keywords
arg
glu
asp
tyr
phe
Prior art date
Application number
DK05107898T
Other languages
Danish (da)
English (en)
Inventor
Frank Mattner
Original Assignee
Frank Mattner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Frank Mattner filed Critical Frank Mattner
Application granted granted Critical
Publication of DK1679319T3 publication Critical patent/DK1679319T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
DK05107898T 2003-01-14 2004-01-13 Fremgangsmåde til forebyggelse og behandling af Alzheimers sygdom (AD) DK1679319T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT362003 2003-01-14
AT0146403A AT413945B (de) 2003-01-14 2003-09-17 Impfstoff für die alzheimer-krankheit
PCT/EP2004/000162 WO2004062556A2 (fr) 2003-01-14 2004-01-13 Procedes de prevention et de traitement de la maladie d'alzheimer

Publications (1)

Publication Number Publication Date
DK1679319T3 true DK1679319T3 (da) 2008-01-28

Family

ID=32714004

Family Applications (2)

Application Number Title Priority Date Filing Date
DK05107898T DK1679319T3 (da) 2003-01-14 2004-01-13 Fremgangsmåde til forebyggelse og behandling af Alzheimers sygdom (AD)
DK04701585.4T DK1583774T3 (da) 2003-01-14 2004-01-13 Fremgangsmåder til forebyggelse og behandling af alzheimers sygdom

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK04701585.4T DK1583774T3 (da) 2003-01-14 2004-01-13 Fremgangsmåder til forebyggelse og behandling af alzheimers sygdom

Country Status (14)

Country Link
US (2) US7732568B2 (fr)
EP (2) EP1583774B1 (fr)
JP (2) JP4547373B2 (fr)
CN (2) CN102526699A (fr)
AT (3) AT413945B (fr)
CA (1) CA2513218C (fr)
CY (2) CY1107146T1 (fr)
DE (2) DE602004009705T2 (fr)
DK (2) DK1679319T3 (fr)
ES (2) ES2296084T3 (fr)
PL (1) PL209989B1 (fr)
PT (2) PT1679319E (fr)
SI (1) SI1583774T1 (fr)
WO (1) WO2004062556A2 (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070010435A1 (en) 2002-12-19 2007-01-11 New York University Method for treating amyloid disease
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
AT413336B (de) * 2003-09-12 2006-02-15 Mattner Frank Dr Apherese-vorrichtung
JP2007522119A (ja) * 2004-01-28 2007-08-09 キュリックス エーピーエス アミロイド関連疾患用ワクチンとしてのアミロイドタンパク質のコンジュゲート
AT500483B1 (de) * 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
AT413946B (de) * 2004-07-13 2006-07-15 Mattner Frank Dr Impfstoff gegen die alzheimer-krankheit
PT1976877E (pt) 2005-11-30 2014-04-29 Abbvie Inc Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações
BRPI0619249A2 (pt) 2005-11-30 2011-09-20 Abbott Lab anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos
MX2008007477A (es) * 2005-12-12 2008-09-03 Ac Immune Sa Anticuerpos monoclonales especificos 1-42 beta con propiedades terapeuticas.
EP1878747A1 (fr) 2006-07-11 2008-01-16 greenovation Biotech GmbH Anticorps glyco-modifiés
NZ574188A (en) 2006-07-14 2012-05-25 Ac Immune Sa Humanized antibody against amyloid beta
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (fr) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Méthode de traitement d'amyloïdoses
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
DK2170389T3 (en) * 2007-06-12 2015-01-19 Ac Immune Sa Humanized antibodies against amyloid beta
US8048420B2 (en) * 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
EP2650308A3 (fr) * 2007-10-05 2014-11-12 Genentech, Inc. Utilisation d'anticorps anti-beta amyloide aux maladies oculaires
EP2205631B1 (fr) * 2007-10-05 2016-11-23 Genentech, Inc. Anticorps humanisé
EP2586795B1 (fr) * 2007-10-05 2018-05-16 Genentech, Inc. Utilisation d'anticorps anti-beta amyloide aux maladies oculaires
WO2009054537A1 (fr) 2007-10-25 2009-04-30 Kagoshima University VACCIN PEPTIDIQUE METTANT EN ŒUVRE UNE MOLÉCULE MIMÉTIQUE DE PEPTIDE β- AMYLOÏDE
CN104098695B (zh) * 2007-10-29 2018-09-07 道健康生活医药株式会社 抗体及其应用
AU2009236583B2 (en) 2008-04-17 2015-07-16 Declion Holdings Llc Design and synthesis of directed sequence polymer compositions and antibodies thereof for the treatment of protein conformational disorders
AT506819B1 (de) * 2008-06-12 2011-06-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzin zur behandlung von alzheimer-krankheit
AT509611B1 (de) * 2008-06-12 2012-04-15 Affiris Forschungs-Und Entwicklungs Gmbh Vakzin
WO2009149487A2 (fr) * 2008-06-12 2009-12-17 Affiris Ag Composés destinés au traitement de symptômes associés à la maladie de parkinson
EP2558494B1 (fr) 2010-04-15 2018-05-23 AbbVie Inc. Protéines de liaison à la bêta amyloïde
AU2011282536B2 (en) 2010-07-30 2015-12-24 Ac Immune S.A. Safe and functional humanized anti beta-amyloid antibody
CN105348387B (zh) 2010-08-14 2020-08-25 Abbvie 公司 β淀粉样蛋白结合蛋白
US20120328605A1 (en) * 2010-10-27 2012-12-27 Daniel Larocque Compositions and uses
GB201113570D0 (en) * 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
ES2496341T3 (es) 2011-10-04 2014-09-18 Affiris Ag Procedimiento para detectar anticuerpos Aß-específicos en una muestra biológica
EP2787347A1 (fr) 2013-04-03 2014-10-08 Affiris AG Procédé pour la détection d'anticorps Aß-spécifiques dans un échantillon biologique
US10381614B2 (en) * 2013-04-17 2019-08-13 Samsung Sdi Co., Ltd. Battery module
WO2015165961A1 (fr) 2014-04-29 2015-11-05 Affiris Ag Traitement et prévention de la maladie d'alzheimer
KR102857456B1 (ko) 2015-11-03 2025-09-08 에이씨 이뮨 에스에이 인간 환자에서 자가-항원에 대한 예방접종을 위한 방법
CN105237628B (zh) * 2015-11-17 2018-08-07 南开大学 一种用于治疗阿尔兹海默症的多肽
CN107022019B (zh) * 2016-11-24 2020-10-30 桂林医学院 一种用于脑内降铁除自由基的多肽、制备方法与应用
EP3658172A4 (fr) 2017-07-25 2021-05-05 TrueBinding, Inc. Traitement du cancer par blocage de l'interaction de tim-3 et de son ligand
CN113711036B (zh) 2019-01-30 2025-03-18 真和制药有限公司 抗gal3抗体及其用途
CN116157151A (zh) 2020-05-26 2023-05-23 真和制药有限公司 通过阻断半乳凝素-3治疗炎性疾病的方法
US20250186580A1 (en) 2022-02-28 2025-06-12 Tridem Bioscience Gmbh & Co Kg A CONJUGATE COMPRISING AT LEAST A ß-GLUCAN

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) * 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US5650489A (en) * 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
GB9022190D0 (en) * 1990-10-12 1990-11-28 Perham Richard N Immunogenic material
US5639603A (en) * 1991-09-18 1997-06-17 Affymax Technologies N.V. Synthesizing and screening molecular diversity
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6088993A (en) 1999-02-05 2000-07-18 Irace; Francisco D. Closure system
AU3158900A (en) 1999-02-25 2000-09-14 Smithkline Beecham Biologicals (Sa) Immunogens comprising a peptide and a carrier derived from h.influenzae protein
US6703491B1 (en) * 1999-03-17 2004-03-09 Exelixis, Inc. Drosophila sequences
ES2344189T3 (es) * 1999-09-03 2010-08-20 RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH & INDUSTRIAL DEVELOPMENT LTD. Agentes, composiciones y metodos que los utilizan utiles en el tratamiento o la prevencion de la enfermedad de alzheimer.
WO2001064008A2 (fr) 2000-03-03 2001-09-07 Smithkline Beecham Biologicals S.A. Vaccins
GB0024200D0 (en) * 2000-10-03 2000-11-15 Smithkline Beecham Sa Component vaccine
DE50111493D1 (de) 2001-09-03 2007-01-04 Bio Life Science Forschungs & Entwicklungsgesellschaft Mbh Antigen-Mimotope und Vakzine gegen Krebserkrankungen
DE60232691D1 (de) * 2002-05-07 2009-07-30 Agronomique Inst Nat Rech Screeningverfahren für PP1-wechselwirkende Polypeptide oder Proteine, Peptide, die die Bindung von PP1c an die Proteine Bcl-2, BCL-XL und BCL-W hemmen, und ihre Verwendung

Also Published As

Publication number Publication date
DE602004009705D1 (de) 2007-12-06
EP1583774B1 (fr) 2010-02-24
EP1679319B1 (fr) 2007-10-24
WO2004062556A3 (fr) 2004-09-16
CA2513218A1 (fr) 2004-07-29
PL378333A1 (pl) 2006-03-20
WO2004062556A8 (fr) 2004-10-21
CN102526699A (zh) 2012-07-04
ES2296084T3 (es) 2008-04-16
DK1583774T3 (da) 2010-05-03
SI1583774T1 (sl) 2010-06-30
ATE376559T1 (de) 2007-11-15
US20110015131A1 (en) 2011-01-20
EP1679319A1 (fr) 2006-07-12
JP5282058B2 (ja) 2013-09-04
JP2010174024A (ja) 2010-08-12
PT1679319E (pt) 2008-01-10
PT1583774E (pt) 2010-04-07
CN1826354A (zh) 2006-08-30
ES2339447T3 (es) 2010-05-20
US20060111301A1 (en) 2006-05-25
AT413945B (de) 2006-07-15
US7732568B2 (en) 2010-06-08
PL209989B1 (pl) 2011-11-30
JP4547373B2 (ja) 2010-09-22
HK1091499A1 (en) 2007-01-19
ES2339447T8 (es) 2011-05-26
ATA14642003A (de) 2005-11-15
AU2004204349A1 (en) 2004-07-29
EP1583774A2 (fr) 2005-10-12
DE602004025668D1 (de) 2010-04-08
DE602004009705T2 (de) 2008-06-05
CY1107146T1 (el) 2012-05-23
CN1826354B (zh) 2014-01-08
WO2004062556A2 (fr) 2004-07-29
CY1110634T1 (el) 2015-04-29
JP2006515876A (ja) 2006-06-08
ATE458753T1 (de) 2010-03-15
CA2513218C (fr) 2013-06-25

Similar Documents

Publication Publication Date Title
DK1583774T3 (da) Fremgangsmåder til forebyggelse og behandling af alzheimers sygdom
TW200602071A (en) Methods for preventing and treating alzheimer's disease (ad)
AT500379B1 (de) Tau-proteine
NO20045021L (no) Immunologiske metoder og preparater for behandling av Alzheimers sykdom
AU2002302255A1 (en) Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
ATE283289T1 (de) Monoklonale antikörper, antigene sowie diagnose und therapie von bösartigen krankheiten
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
NO20022531L (no) Vaksine for forebyggelse og behandling av Alzheimer- og amyloidrelaterte sykdommer
BR0213565A (pt) Anticorpo de anti-tnf alfa modificado
WO2004006952A3 (fr) Vaccin therapeutique contre la tuberculose
DK2075007T3 (da) Behandling af Alzheimers sygdom
WO2001068708A3 (fr) ANTICORPS HUMAINS SPECIFIQUES DE FAP-$g(a)
MA28418B1 (fr) Anticorps liant un recepteur de l'interleucine 4
NO20076021L (no) Antistoffer rettet mot amyloid-betapeptid og metoder som anvender de samme
BR0211296A (pt) Peptìdeo imunogênico derivado da proteìna g do vrs do sub-grupo a ou b, sequência de ácido nucleico, composição farmacêutica, anticorpos policlonais ou monoclonais, kit de diagnóstico, utilização de um peptìdeo imunogênico, e, conjugado
WO2004076614A3 (fr) Sequences d'acide nucleique humaines issues de carcinomes de la prostate
EP2628750A3 (fr) Identification ciblée de peptides immunogènes
WO2004113386A3 (fr) Protéines d'hirudine modifiée et épitopes de lymphocytes t dans l'hirudine
ATE346091T1 (de) Neues diagnostisches reagens und kit zur erkennung von rickettsiose
ATE395356T1 (de) Oberflächenprotein aus neisserien
BG101846A (bg) Варианти на човешка дезоксирибонуклеаза i
WO2007030771A3 (fr) Identification ciblee de peptides immunogenes
ATE512981T1 (de) Identifizierung von ses-3 (spr-5) aus c. elegans sowie dessen verwendungen
DK1569961T3 (da) Splice variant af det menneskelige hypofysevæksthormon
ATE338063T1 (de) Diagnostische verwendungen des t-zell proteins tzon7, der davon abgeleiteten peptide und des antikörpers